Stocks and Investing
Stocks and Investing
Mon, July 29, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Laura Chico Reiterated (VRDN) at Buy and Held Target at $42 on, Jul 29th, 2024
Laura Chico of Wedbush, Reiterated "Viridian Therapeutics, Inc." (VRDN) at Buy and Held Target at $42 on, Jul 29th, 2024.
Laura has made no other calls on VRDN in the last 4 months.
There are 7 other peers that have a rating on VRDN. Out of the 7 peers that are also analyzing VRDN, 2 agree with Laura's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Kalpit Patel of "B. Riley Securities" Downgraded from Strong Buy to Hold and Decreased Target to $20 on, Thursday, May 9th, 2024
- Michael Higgins of "Ladenburg Thalmann" Downgraded from Strong Buy to Hold on, Thursday, May 9th, 2024
These are the ratings of the 5 analyists that currently disagree with Laura
- Douglas Tsao of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $27 on, Tuesday, July 16th, 2024
- Andy Chen of "Wolfe Research" Initiated at Buy on, Tuesday, June 11th, 2024
- Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $30 on, Tuesday, June 11th, 2024
- Richard Law of "Goldman Sachs" Initiated at Strong Buy and Held Target at $23 on, Thursday, June 6th, 2024
- Leland Gershell of "Oppenheimer" Maintained at Buy with Decreased Target to $31 on, Thursday, May 9th, 2024
Contributing Sources